0.00
-5.56%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About S2Medical AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker S2M.ST. It has been listed since 28 November 2018. In the fiscal year to 31 December 2025, it reported revenue of SEK 14.4m and a net loss of SEK 10.1m. At that date it held total assets of SEK 16.9m and shareholders' equity of SEK 9.9m.
S2Medical AB engages in research and development in biotechnology. The company is headquartered in Linkoping, Ostergotland. The company went IPO on 2018-11-28. The firm focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The firm's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The firm is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 28 Nov 2018
- Website
- s2m.se ↗
Leadership
Pay as last reported
- Mr. Amin OmraniIndependent Chairman of the Board
- Mr. Petter SivlerChief Executive Officer
- Oskar JohanssonChief Financial Officer
- Mr. Marten SkogChief Operating Officer, Director
- Mr. Martin ZetterstromDirector
- Mr. Carsten BrowallIndependent Director
- Mr. Roland FrosingIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- S2Medical AB has a focused product portfolio targeting burn and chronic wound healing.
- The company operates a wound healing center called S2Clinic in Sweden.
- It holds distribution rights for Silverlon antimicrobial dressings in Nordic countries.
Weaknesses
- The company's product development is limited to specific medical applications.
- No information is provided about the company's financial performance or market share.
- The company's website is not described as having a strong online presence or user engagement.
Opportunities
- Expanding the distribution of Silverlon antimicrobial dressings beyond Nordic countries.
- Growing demand for advanced wound care solutions in the healthcare sector.
- Potential for further development of the Epiprotect product line based on Eiratex material.
Threats
- Competition from other biotechnology firms in the wound care market.
- Regulatory challenges in the healthcare industry affecting product approvals.
- Dependence on a narrow product portfolio for revenue generation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.